Abstract
Recent studies show that the risk of cardiovascular adverse events for certain traditional non-steroidal anti-inflammatory drugs (NSAIDs) is similar to that of rofecoxib. While these results are focused on ischemic cardiomyopathy, there is little evidence concerning the risk of ischemic stroke/transient ischemic attack and hemorrhagic stroke. Additionally, there is no information on nimesulide and ketoprofen, the most frequently prescribed NSAIDs in Italy, along with diclofenac. This study aims to determine whether the use of NSAIDs is associated with an increased risk of cerebrovascular events in Italy. We performed a case–control analysis nested in a cohort of patients with osteoarthritis between 2002 and 2011 who were newly treated with NSAIDs. The patients were followed until December 31, 2012. Conditional logistic regression was used to estimate odds ratios (ORs) with 95 % confidence intervals (95 % CI) of cerebrovascular events (index date) associated with current (until 30 days before the index date), recent (31–365 days) and past (>365 days) use of NSAIDs. Within a cohort of 29,722 patients, 1566 cases (1546 matched with controls) were identified (incidence rate = 11.0/1000 person–years). The overall rate of cerebrovascular event was not elevated with current NSAIDs overall when compared with past use. Among individual NSAIDs, diclofenac and ketoprofen were the molecules significantly associated with an increased rate of cerebrovascular events (OR = 1.53; 95 % CI 1.04–2.24; OR = 1.62; 95 % CI 1.02–2.58, respectively). The most frequent event was hemorrhagic stroke following the use of ketoprofen (OR = 2.09; 95 % CI 1.05–4.15). Diclofenac and ketoprofen seemed to increase the risk of cerebrovascular events. These findings might influence the choice of NSAIDs according to patient characteristics.
Similar content being viewed by others
References
Deviere J (2002) Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? Eur J Gastroenterol Hepatol 14(Suppl 1):S29–S33
Clark DW, Layton D, Shakir SA (2004) Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf 27:427–456
Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102. doi:10.1056/NEJMoa050493
Baron JA, Sandler RS, Bresalier RS et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372:1756–1764. doi:10.1016/S0140-6736(08)61490-7
EMA (2012) Review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Outcome of a procedure under Article 5(3) of Regulation (EC) No 726/20041
Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559–570. doi:10.1002/pds.3437
Garcia Rodriguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628–1636. doi:10.1016/j.jacc.2008.08.041
De Abajo FJ, Gil MJ, García Poza P et al (2014) Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol, Drug Saf. doi:10.1002/pds.3617
García-Poza P, de Abajo FJ, Gil MJ et al (2015) Risk of ischaemic stroke associated with non-steroidal antiinflammatory drugs and paracetamol: a population-based case-control study. J Thromb Haemost 13(5):708–718
Fosbol EL, Folke F, Jacobsen S et al (2010) Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3:395–405. doi:10.1161/circoutcomes.109.861104
Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 20:1225–1236. doi:10.1002/pds.2227
Gruppo di lavoro OsMed. L'uso dei farmaci in Italia. Rapporto nazionale anno 2011. Roma: Il Pensiero Scientifico Editore, 2012
Piccoliori G Turbil E, Pecchioli S, Sessa E, Cancian M, Lora Aprile P (2007) Italian Pain Research: dati preliminari di una ricerca osservazionale in medicina generale. Riv SIMG:6–11
Wilson N, Sanchez-Riera L, Morros R et al (2015) Drug utilization in patients with OA: a population-based study. Rheumatology 54:860–867. doi:10.1093/rheumatology/keu403
Rahman MM, Kopec JA, Anis AH et al (2013) The risk of cardiovascular disease in patients with osteoarthritis: a prospective longitudinal study. Arthritis Care Res. doi:10.1002/acr.22092
Rahman MM, Kopec JA, Cibere J et al (2013) The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open. doi:10.1136/bmjopen-2013-002624
Coloma PM, Valkhoff VE, Mazzaglia G et al (2013) Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open. doi:10.1136/bmjopen-2013-002862
Sterrantino C, Trifiro G, Lapi F et al (2013) Burden of community-acquired pneumonia in Italian general practice. Eur Respir J 42:1739–1742. doi:10.1183/09031936.00128713
Trifiro G, Morabito P, Cavagna L et al (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 72:694–700. doi:10.1136/annrheumdis-2011-201254
Lapi F, Simonetti M, Michieli R et al (2012) Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 50:85–90. doi:10.1016/j.bone.2011.09.048
Mazzaglia G, Ambrosioni E, Alacqua M et al (2009) Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120:1598–1605. doi:10.1161/CIRCULATIONAHA.108.830299
Filippi A, Vanuzzo D, Bignamini AA et al (2005) Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. Ital Heart J 6:49–51
Bianchini E, Brignoli O, Cricelli C et al (2014) VIII Report Health Search. Anno 2013/2014. Firenze
Breslow NE (1996) Statistics in epidemiology: the case-control study. J Am Stat Assoc 91:14–28
Salas M, Hofman A, Stricker BH (1999) Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149:981–983. doi:10.1093/oxfordjournals.aje.a009758
Hawker GA, Croxford R, Bierman AS et al (2014) All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. doi:10.1371/journal.pone.0091286
Suissa S (2015) The Quasi-cohort approach in pharmacoepidemiology. Epidemiology 26:242–246. doi:10.1097/EDE.0000000000000221
McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633–1644. doi:10.1016/S0093-3619(08)70535-5
Chuang S-Y, Yu Y, Huey-Herng Sheu W et al (2015) Association of short-term use of nonsteroidal anti-inflammatory drugs with stroke in patients with hypertension. Stroke 46:996–1003. doi:10.1161/STROKEAHA.114.007932
Park K, Bavry AA (2014) Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Heal Risk Manag 10:25–32. doi:10.2147/vhrm.s54159
Bowman TS, Gaziano JM, Kase CS et al (2006) Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men. Neurology 67:820–823. doi:10.1212/01.wnl.0000233981.26176.e1
Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477–484. doi:10.1001/archinte.1993.00410040045007
Johnson AG, Nguyen TV, Day RO (1994) Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121:289–300. doi:10.7326/0003-4819-121-4-199408150-00011
Riendeau D, Percival MD, Brideau C et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558–566
Giuliano F, Ferraz JGP, Pereira R et al (2001) Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 426:95–103. doi:10.1016/S0014-2999(01)01207-9
Warner TD, Giuliano F, Vojnovic I et al (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci 96:7563–7568
Famaey JP (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 46:437–446
Rainsford KD (2006) Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 14:120–137. doi:10.1007/s10787-006-1505-9
Lapeyre-Mestre M, Grolleau S, Montastruc JL (2013) Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 27:223–230. doi:10.1111/j.1472-8206.2011.00991.x
Graff J, Skarke C, Klinkhardt U et al (2007) Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 5:2376–2385. doi:10.1111/j.1538-7836.2007.02782.x
Sacco S, Stracci F, Cerone D et al (2011) Epidemiology of stroke in Italy. Int J Stroke 6:219–227. doi:10.1111/j.1747-4949.2011.00594.x
Istituto Superiore di Sanità. Progetto CUORE—Epidemiology and prevention of ischaemic heart diseases. http://www.cuore.iss.it/indicatori/popolazione.asp. Accessed 26 June 2015
Fox MP, Lash TL, Greenland S (2005) A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol 34:1370–1376. doi:10.1093/ije/dyi184
Yood MU, Campbell UB, Rothman KJ et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968. doi:10.1002/pds.1454
Andersohn F, Schade R, Suissa S et al (2006) Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 37:1725–1730. doi:10.1161/01.STR.0000226642.55207.94
Salvo F, Antoniazzi S, Duong M et al (2014) Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf. doi:10.1517/14740338.2014.907792
Wacholder S, Silverman DT, McLaughlin JK et al (1992) Selection of controls in case-control studies. III. Design options. Am J Epidemiol 135:1042–1050
Farmadati Italia. http://www.farmadati.it/. Accessed 19 June 2015
Kristensen P (1992) Bias from nondifferential but dependent misclassification of exposure and outcome. Epidemiology 3:210–215. doi:10.1097/00001648-199205000-00005
Italian Medicines Agency (2012) Note number 66 on the prescription of nonsteroidal anti-inflammatory drug. Italy
Lapi F, Azoulay L, Yin H et al (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346:e8525. doi:10.1136/bmj.e8525
Bannuru RR, Schmid CH, Kent DM et al (2015) Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 162:46–54. doi:10.7326/M14-1231
Burke A, Smyth EM, Fitzgerald GA (2006) Analgesic-antipyretic agents: pharmacotherapy of gout. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman's The pharmacological basis of therapeutics, 11th edn. Mc Graw-Hill, New York, p 671-715
Acknowledgments
Angelini supported this study but had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
F. Lapi and I. Cricelli provided consultations in protocol preparation for epidemiological studies and data analyses for IBSA and Angelini. C. Cricelli and P. A. Lora Aprile provided clinical consultations for IBSA, Angelini, Alfa Wasserman, Pfizer, ProStrakan and Molteni. A. Fanelli provided clinical consultations for Abbivie and IBSA. C. Piccinni, M. Levi and M. Simonetti have no conflicts of interest to disclose.
Statement of human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
None.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lapi, F., Piccinni, C., Simonetti, M. et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case–control study. Intern Emerg Med 11, 49–59 (2016). https://doi.org/10.1007/s11739-015-1288-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-015-1288-3